Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 5th edition, 486 pages Free download

Lung Cancer

Free Subscription Articles published in Lancet Retrieve available abstracts of 22 articles: HTML format

Single Articles

August 2020
1. SZTURZ P, Vermorken JB
   Further clinical interpretation and implications of KEYNOTE-048 findings.
   Lancet. 2020;396:379.
   PubMed    
   
   
   
2. MCCAW ZR, Ludmir EB, Kim DH, Wei LJ, et al
   Further clinical interpretation and implications of KEYNOTE-048 findings.
   Lancet. 2020;396:378-379.
   PubMed    
   
   
   
3. REVANNASIDDAIAH S, Devadas SK, Maka VV, Kilara N, et al
   Further clinical interpretation and implications of KEYNOTE-048 findings.
   Lancet. 2020;396:378.
   PubMed    
   
   
   May 2020
4. HARRIS DA, Willis J, Tomann M
   A new era of coal workers' pneumoconiosis: decades in mines may not be required.
   Lancet. 2020;395:e82.
   PubMed    
   
   
   November 2019
5. LUDMIR EB, McCaw ZR, Grossberg AJ, Wei LJ, et al
   Quantifying the benefit of non-small-cell lung cancer immunotherapy.
   Lancet. 2019;394:1904.
   PubMed    
   
   
   
6. MOK TSK, Zhang J, Lopes G
   Quantifying the benefit of non-small-cell lung cancer immunotherapy - Authors' reply.
   Lancet. 2019;394:1904-1905.
   PubMed    
   
   
   
7. THE LANCET
   Lung cancer: some progress, but still a lot more to do.
   Lancet. 2019;394:1880.
   PubMed    
   
   
   October 2019
8. PAZ-ARES L, Dvorkin M, Chen Y, Reinmuth N, et al
   Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
   Lancet. 2019 Oct 4. pii: S0140-6736(19)32222.
   PubMed     Abstract available
   
   
   
9. GOETZE TO
   Immunotherapy: a new era in small-cell lung cancer.
   Lancet. 2019 Oct 4. pii: S0140-6736(19)32235.
   PubMed    
   
   
   September 2019
10. ZHOU M, Wang H, Zeng X, Yin P, et al
    Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet. 2019;394:1145-1158.
    PubMed     Abstract available
    
    
    May 2019
11. LOO BW JR, Diehn M
    SABR-COMET: harbinger of a new cancer treatment paradigm.
    Lancet. 2019;393:2013-2014.
    PubMed    
    
    
    
12. SMIT EF, de Langen AJ
    Pembrolizumab for all PD-L1-positive NSCLC.
    Lancet. 2019;393:1776-1778.
    PubMed    
    
    
    April 2019
13. MOK TSK, Wu YL, Kudaba I, Kowalski DM, et al
    Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
    Lancet. 2019 Apr 4. pii: S0140-6736(18)32409.
    PubMed     Abstract available
    
    
    September 2017
14. BARNETT R
    Lung cancer.
    Lancet. 2017;390:928.
    PubMed    
    
    
    August 2017
15. RIDKER PM, MacFadyen JG, Thuren T, Everett BM, et al
    Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32247.
    PubMed     Abstract available
    
    
    
16. JENKINS BJ
    Potential efficacy of interleukin-1beta inhibition in lung cancer.
    Lancet. 2017 Aug 25. pii: S0140-6736(17)32289.
    PubMed    
    
    
    May 2017
17. ROSS RJ, Mann NC
    Synchronous distal phalangeal metastases from primary non-small-cell lung cancer.
    Lancet. 2017 May 25. pii: S0140-6736(17)31288.
    PubMed    
    
    
    
18. HIDA T, Nokihara H, Kondo M, Kim YH, et al
    Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Lancet. 2017 May 10. pii: S0140-6736(17)30565.
    PubMed     Abstract available
    
    
    
19. GAINOR JF, Shaw AT
    J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.
    Lancet. 2017 May 10. pii: S0140-6736(17)31074.
    PubMed    
    
    
    April 2017
20. LANGLEY RE, Nankivell M, Barton R, Faivre-Finn C, et al
    Whole brain radiotherapy for non-small cell lung cancer - Authors' reply.
    Lancet. 2017;389:1395-1396.
    PubMed    
    
    
    
21. ZHU J, Kang M, Fan X
    Whole brain radiotherapy for non-small cell lung cancer.
    Lancet. 2017;389:1395.
    PubMed    
    
    
    
22. CAGNEY DN, Alexander BM, Aizer AA
    Whole brain radiotherapy for non-small cell lung cancer.
    Lancet. 2017;389:1394-1395.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: